- ►diabetesjournals.org JB Buse, RR Henry, J Han, DD Kim, MS … - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS—At week 30, HbA 1c changes from baseline were −0.86 ± 0.11, −0.46
± 0.12, and 0.12 ± 0.09% (±SE) in the 10-μg, 5-μg, and placebo arms,
respectively (adjusted P < 0.001). Of evaluable subjects with baseline HbA ... Cited by 454 - Related articles - BL Direct - All 13 versions
A Schweizer, A Couturier, JE Foley, S Dejager - Diabetic Medicine, 2007 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 89 - Related articles - BL Direct - All 4 versions
- ►nih.gov K Nagashima, C Lopez, D Donovan, C Ngai, N … - Journal of Clinical Investigation, 2005 - Am Soc Clin Investig Elevated plasma levels of VLDL triglycerides (TGs) are characteristic of
patients with type 2 diabetes mellitus (T2DM) and are associated with increased
production rates (PRs) of VLDL TGs and apoB. Lipoprotein lipase–mediated ... Cited by 88 - Related articles - All 8 versions
PA Sarafidis, GL Bakris - Kidney international, 2006 - nature.com The global epidemic of diabetes mellitus has led to a continuous increase in the
prevalence of diabetic nephropathy over the past years. Thus, diabetic
nephropathy is currently the number one cause of end-stage renal disease in ... Cited by 72 - Related articles - BL Direct - All 4 versions
- ►adisonline.com [PDF] J Waugh, GM Keating, GL Plosker, S … - Drugs, 2006 - ingentaconnect.com 0012-6667/06/0001-0085/$44.95/0 2006 Adis Data Information BV. All rights
reserved. ... A Review of its Use in Type 2 Diabetes Mellitus ... John Waugh,
Gillian M. Keating, Greg L. Plosker, Stephanie Easthope and Dean M. Robinson Cited by 64 - Related articles - BL Direct - All 7 versions
- ►diabetesjournals.org J Gerich, P Raskin, L Jean-Louis, D … - Diabetes Care, 2005 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—We conducted a randomized, multicenter,
double-masked, 2-year study of 428 drug-naïve patients with type 2 diabetes.
Patients received 120 mg ac nateglinide or 1.25 mg qd glyburide plus 500 mg ... Cited by 43 - Related articles - BL Direct - All 10 versions
G Belcher, C Lambert, G Edwards, R … - Diabetes research and clinical practice, 2005 - Elsevier This analysis compares the safety and tolerability of pioglitazone (a
thiazolidinedione), metformin (a biguanide), and gliclazide (a sulfonylurea).
Data collected from four 1-year, double-blind studies comparing treatment ... Cited by 36 - Related articles - All 5 versions
DJ Betteridge, B Verges - Diabetologia, 2005 - Springer Abstract Aims/hypothesis: The aim of this study was to determine the long-term
effects of pioglitazone add-on to metformin or sulphonylurea on plasma lipids
and lipo- proteins. Materials and methods: The effects of piogli- tazone ... Cited by 37 - Related articles - BL Direct - All 3 versions
MO Goodarzi, M Bryer-Ash - Diabetes Obesity and Metabolism, 2005 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 28 - Related articles - BL Direct - All 4 versions
